Rifamycin

Identification

Summary

Rifamycin is an antibacterial used to treat traveler's diarrhea.

Brand Names

Aemcolo

Generic Name

Rifamycin

DrugBank Accession Number

DB11753

Background

Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.²

Rifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.¹

Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review.¹⁰ This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.¹¹

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Rifamycin (DB11753)

×

Close

Weight

Average: 697.778
Monoisotopic: 697.309825957

Chemical Formula

C₃₇H₄₇NO₁₂

Synonyms

• Rifamicina
• Rifamicine SV
• Rifamycin
• Rifamycin SV
• Rifamycine
• Rifamycinum
• Rifomycin SV

External IDs

• M-14

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Rifamycin is indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of E. coli. The status of the disease should not be complicated by fever or blood in the stool. To prevent drug-resistant bacteria, it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacteria.¹²

Travallers' diarrhea is very common problem affecting 20-60% of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad. This condition is rarely life threatening but in severe cases it can produce dehydration and sepsis. The most common cause of travellers' diarrhea is a pathogen and from the pathogens identified, bacteria is the most common cause followed by norovirus, rotavirus and similar viruses.³

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Treatment of	Not complicated by fever, not complicated by bloody stool traveler's diarrhea caused by noninvasive strains of escherichia coli		••••••••••••	•••••		••••••• •••••••• •••••••
Used in combination to treat	Susceptible bacterial infections	Combination Product in combination with: Lidocaine (DB00281)	••••••••••••			•••••••••• ••••••••• ••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Rifamycin is known to be effective against Gram-positive and Gram-negative pathogens and mycobacteria. It is very effective against E. coli reporting a MIC90 of 64-128 mcg/ml without showing cross-resistance with other antimicrobial agents.⁴

The specific indication of rifamycin is extremely important as ther were previous reports that indicated a high risk factor in the generation of resistant E. coli strains in patients with inflammatory bowel disease.¹³

In clinical trials, rifamycin was tested in a randomized clinical trial of travellers' coming from Mexico and Guatemala. In this trial, rifamycin was proven to significantly reduce the symptoms of travellers' diarrhea.¹²

Mechanism of action

Rifamycins, as well as all the other members of this group, present an antibacterial mechanism of action related to the inhibition of RNA synthesis. This mechanism of action is done by the strong binding to the DNA-dependent RNA polymerase of prokaryotes. The inhibition of the RNA synthesis is thought to be related with the initiation phase of the process and to involve stacking interactions between the naphthalene ring and the aromatic moiety in the polymerase. As well, it has been suggested that the presence of zinc atoms in the polymerase allows for the binding of phenolic -OH groups of the naphthalene ring.⁹

In eukaryotic cells, the binding is significantly reduced making them at least 100 to 10,000 times less sensitive to the action of rifamycins. The members of the rifamycin family present the same mechanism of action and the structural modifications are usually related to pharmacokinetic properties as well as to the interaction with eukaryotic cells.⁸

Target	Actions	Organism
ADNA-directed RNA polymerase subunit beta	binder	Escherichia coli (strain K12)
ADNA-directed RNA polymerase subunit alpha	binder	Escherichia coli (strain K12)
ADNA-directed RNA polymerase subunit beta'	binder	Escherichia coli (strain K12)

Absorption

Rifamycin has a very poor absorption⁴ and thus, the generation of an oral modified-release formulation using the technology of the multi-matrix structure was required for the generation of the FDA approved product. This preparation allows the delivery of the active ingredient in the distal small bowel and colon without interfering with the flora in the upper gastrointestinal tract.⁵

The multi-matrix is made by a lipophiic matrix surrounded in a hydrophilic matrix which allows for the protection of the active ingredient from dissolution in the intestinal aqueous fluids before it arrives in the cecum. All this matrix is surrounded by a gastro-resistant polymer that only desintegrate in a pH lower than 7.⁶

All this administration-customed formulation allows for a bioavailability of <0.1% and the plasma concentrations are reported to be of <2 ng/ml in patients receiving a dose of 400 mg. This confirms that the site of action of rifamycin stays in the small intestine and colon which prevents the need for dose adjustments in special populations as well as systemic drug interactions.⁶

The reported Cmax, tmax, AUC and mean residence time after a dosage of 250 mg of rifamycin is 36 mg/L, 5 min, 11.84 mg.h/L and 0.49 h respectively.⁶

Volume of distribution

The reported volume of distribution after measured after a dosage of 250 mg of rifamycin is 101.8 L.⁶

Protein binding

The protein binding of rifamycin is of about 80-95%.⁷

Metabolism

When absorbed, rifamycin is mainly metabolzied in hepatocytes and intestinal microsomes to a 25-deacetyl metabolite.⁶

Hover over products below to view reaction partners

• Rifamycin
  • 25-deacetyl-rifamycin

Route of elimination

From the administered dose, 18%, 50% and 21% is recovered in feces during the first 24, 48 and 72h after administration. This will represent about 90% of the administered dose eliminated by the feces while the urinary secretion is negligible.⁶

Half-life

The reported half-life when a dose of 250 mg of rifamycin was administered is 3 h.⁶

Clearance

The reported clearance when a dose of 250 mg of rifamycin was administered is 23.3 L/h.⁶

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

In safety studies with rifamycin, it was reported a potential of hepatotoxicity due to the depletion of glutathione and the generation of reactive oxygen species in liver microsomes. It is important to mention that this effect is mainly observed in the intravenous administration as the oral dosage does not have a significant systemic absorption.⁷

Rifamycin is not genotoxic in bacterial mutation assays, mouse cell mutation assay or mouse bone marrow micronucleus assay. There is no current information about the effects on fertility, overdosage or carcinogenesis.^Label

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The metabolism of 1,2-Benzodiazepine can be increased when combined with Rifamycin.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Rifamycin.
Abiraterone	The metabolism of Abiraterone can be increased when combined with Rifamycin.
Abrocitinib	The metabolism of Abrocitinib can be increased when combined with Rifamycin.
Acalabrutinib	The metabolism of Acalabrutinib can be increased when combined with Rifamycin.

Food Interactions

• Avoid alcohol.
• Take with a full glass of water.
• Take with or without food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Rifamycin sodium	32086GS35Z	14897-39-3	YVOFSHPIJOYKSH-NLYBMVFSSA-M

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Aemcolo	Tablet, delayed release	194 mg/1	Oral	Aries Pharmaceuticals Inc	2019-02-01	2022-04-01
Aemcolo	Tablet, delayed release	194 mg/1	Oral	RedHill Biopharma Ltd	2021-07-01	Not applicable
Aemcolo	Tablet, delayed release	194 mg/1	Oral	RedHill Biopharma Ltd	2021-07-01	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
RIF 125 MG 1 AMPUL	Rifamycin sodium (125 mg) + Lidocaine hydrochloride (5 mg)	Solution	Intramuscular	KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş.	2008-04-17	Not applicable
RIF 250 MG 1 AMPUL	Rifamycin sodium (250 mg) + Lidocaine hydrochloride (10 mg)	Solution	Intramuscular	KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş.	2008-04-17	Not applicable
RIF 250 MG AMPUL, 100 ADET	Rifamycin sodium (250 mg) + Lidocaine hydrochloride (10 mg)	Solution	Intramuscular	KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş.	2020-08-14	Not applicable
RIFETEM 125 MG / 1,5 ML AMPUL, 1 ADET	Rifamycin (125 mg/1.5ml) + Lidocaine hydrochloride (5 mg/1.5ml)	Solution	Intramuscular	MENARİNİ SAĞLIK VE İLAÇ SAN. VE TİC. A.Ş.	1996-05-03	2021-03-16
RIFETEM 250 MG / 3 ML AMPUL, 1 ADET	Rifamycin (250 mg/3ml) + Lidocaine hydrochloride (10 mg/3ml)	Solution	Intramuscular	İ.E. ULAGAY İLAÇ SAN. TÜRK A.Ş.	1996-05-03	2024-01-23

Categories

ATC Codes

S01AA16 — Rifamycin

• S01AA — Antibiotics
• S01A — ANTIINFECTIVES
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S02AA12 — Rifamycin

• S02AA — Antiinfectives
• S02A — ANTIINFECTIVES
• S02 — OTOLOGICALS
• S — SENSORY ORGANS

D06AX15 — Rifamycin

• D06AX — Other antibiotics for topical use
• D06A — ANTIBIOTICS FOR TOPICAL USE
• D06 — ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
• D — DERMATOLOGICALS

A07AA13 — Rifamycin

• A07AA — Antibiotics
• A07A — INTESTINAL ANTIINFECTIVES
• A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
• A — ALIMENTARY TRACT AND METABOLISM

J04AB03 — Rifamycin

• J04AB — Antibiotics
• J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS
• J04 — ANTIMYCOBACTERIALS
• J — ANTIINFECTIVES FOR SYSTEMIC USE

Drug Categories

• Alimentary Tract and Metabolism
• Anti-Bacterial Agents
• Anti-Infective Agents
• Antibiotics for Topical Use
• Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
• Antiinfectives for Systemic Use
• Antimycobacterials
• Antirheumatic Agents
• Cytochrome P-450 CYP1A2 Inhibitors
• Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2B6 Inducers
• Cytochrome P-450 CYP2B6 Inducers (strength unknown)
• Cytochrome P-450 CYP2B6 Inhibitors
• Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2C19 Inducers
• Cytochrome P-450 CYP2C19 Inducers (strong)
• Cytochrome P-450 CYP2C19 Inhibitors
• Cytochrome P-450 CYP2C19 inhibitors (strength unknown)
• Cytochrome P-450 CYP2C8 Inducers
• Cytochrome P-450 CYP2C8 Inducers (strength unknown)
• Cytochrome P-450 CYP2C8 Inhibitors
• Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2C9 Inducers
• Cytochrome P-450 CYP2C9 Inducers (strength unknown)
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
• Cytochrome P-450 CYP3A Inducers
• Cytochrome P-450 CYP3A Inducers (strong)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A4 Inducers
• Cytochrome P-450 CYP3A4 Inducers (strong)
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
• Cytochrome P-450 Enzyme Inducers
• Cytochrome P-450 Enzyme Inhibitors
• Dermatologicals
• Drugs for Treatment of Tuberculosis
• Heterocyclic Compounds, Fused-Ring
• Intestinal Antiinfectives
• Lactams, Macrocyclic
• MATE 1 Inhibitors
• MATE inhibitors
• OATP1B1/SLCO1B1 Inhibitors
• OATP1B3 inhibitors
• Ophthalmologicals
• Organic Anion Transporting Polypeptide 2B1 Inhibitors
• Otologicals
• P-glycoprotein inhibitors
• P-glycoprotein substrates
• Rifamycin Antibacterial
• Rifamycins
• Sensory Organs

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.

Kingdom

Organic compounds

Super Class

Phenylpropanoids and polyketides

Class

Macrolactams

Sub Class

Not Available

Direct Parent

Macrolactams

Alternative Parents

Naphthofurans / Naphthols and derivatives / Benzofurans / Coumarans / Aryl alkyl ketones / Hydroquinones / 1-hydroxy-2-unsubstituted benzenoids / Ketals / Secondary carboxylic acid amides / Secondary alcohols / Carboxylic acid esters / Lactams / Dialkyl ethers / Oxacyclic compounds / Azacyclic compounds / Polyols / Monocarboxylic acids and derivatives / Organopnictogen compounds / Hydrocarbon derivatives / Organonitrogen compounds / Organic oxides

show 11 more

Substituents

1-hydroxy-2-unsubstituted benzenoid / 1-naphthol / Acetal / Alcohol / Aromatic heteropolycyclic compound / Aryl alkyl ketone / Aryl ketone / Azacycle / Benzenoid / Benzofuran / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Carboxylic acid ester / Coumaran / Dialkyl ether / Ether / Hydrocarbon derivative / Hydroquinone / Ketal / Ketone / Lactam / Macrolactam / Monocarboxylic acid or derivatives / Naphthalene / Naphthofuran / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Polyol / Secondary alcohol / Secondary carboxylic acid amide

show 27 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

acetate ester, polyphenol, lactam, macrocycle, cyclic ketal, rifamycin (CHEBI:29673) / Ansamycins and related polyketides (C12044) / Ansamycins and related polyketides (LMPK05000005)

Affected organisms

• Escherichia coli

Chemical Identifiers

UNII

DU69T8ZZPA

CAS number

6998-60-3

InChI Key

HJYYPODYNSCCOU-ODRIEIDWSA-N

InChI

InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1

IUPAC Name

(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O

References

General References

1. Lin SW, Lin CJ, Yang JC: Rifamycin SV MMX for the treatment of traveler's diarrhea. Expert Opin Pharmacother. 2017 Aug;18(12):1269-1277. doi: 10.1080/14656566.2017.1353079. Epub 2017 Jul 27. [Article]
2. Sensi P: History of the development of rifampin. Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S402-6. [Article]
3. Barrett J, Brown M: Travellers' diarrhoea. BMJ. 2016 Apr 19;353:i1937. doi: 10.1136/bmj.i1937. [Article]
4. Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP: Enteropathogens and chronic illness in returning travelers. N Engl J Med. 2013 May 9;368(19):1817-25. doi: 10.1056/NEJMra1207777. [Article]
5. Rosette C, Buendia-Laysa F Jr, Patkar S, Moro L, Celasco G, Bozzella R, Ajani M, Gerloni M: Anti-inflammatory and immunomodulatory activities of rifamycin SV. Int J Antimicrob Agents. 2013 Aug;42(2):182-6. doi: 10.1016/j.ijantimicag.2013.04.020. Epub 2013 Jun 5. [Article]
6. Di Stefano AF, Rusca A, Loprete L, Droge MJ, Moro L, Assandri A: Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers. Antimicrob Agents Chemother. 2011 May;55(5):2122-8. doi: 10.1128/AAC.01504-10. Epub 2011 Mar 14. [Article]
7. Aristoff PA, Garcia GA, Kirchhoff PD, Showalter HD: Rifamycins--obstacles and opportunities. Tuberculosis (Edinb). 2010 Mar;90(2):94-118. doi: 10.1016/j.tube.2010.02.001. Epub 2010 Mar 16. [Article]
8. Floss HG, Yu TW: Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. doi: 10.1021/cr030112j. [Article]
9. Kerr P. (2013). Fighting multidrug resistance with herbal extracts, essential oils and their components. Academic Press.
10. FDA approvals [Link]
11. EMA approvals [Link]
12. FDA news [Link]
13. Bentham Science [Link]
14. FDA Approved Drug Products: AEMCOLO (rifamycin) delayed-release tablets, for oral use [Link]

External Links

KEGG Drug

D02549

KEGG Compound

C12044

PubChem Substance

347911235

ChemSpider

16735998

BindingDB

50391000

RxNav

35616

ChEBI

29673

ChEMBL

CHEMBL437765

ZINC

ZINC000169633673

Wikipedia

Rifamycin

FDA label

Download (349 KB)

MSDS

Download (23.5 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Impacted Third Molar Tooth	1
4	Recruiting	Treatment	Pulmonology	1
3	Completed	Treatment	Traveler's Diarrhea	2
3	Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19) / Human Immunodeficiency Virus (HIV) Infections / Tuberculosis (TB)	1
2	Completed	Treatment	Cirrhosis of the Liver / Hepatic Encephalopathy (HE)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet, delayed release	Oral	194 mg/1
Tablet
Solution	Intramuscular
Solution	Intramuscular	125 mg
Solution	Intramuscular	250 mg
Injection	Intramuscular	125 mg/1.5ml
Solution	Topical	1 g
Solution / drops	Ophthalmic	1 %
Solution / drops	Auricular (otic)	1 %
Injection, solution	Intramuscular	250 MG/3ML
Injection, solution	Intravenous	250 MG/10ML
Injection, solution	Intravenous	500 MG/10ML
Injection, solution	Intramuscular
Solution / drops	Ophthalmic	10 mg/5ml
Solution / drops	Auricular (otic)	100 mg/10ml
Tablet		200 MG

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US8741948	No	2014-06-03	2025-05-03
US8263120	No	2012-09-11	2025-05-03
US8529945	No	2013-09-10	2025-05-03
US8486446	No	2013-07-16	2025-05-03

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	171 ºC	'MSDS'
boiling point (°C)	972.8 ºC at 760 mm Hg	'MSDS'
water solubility	Insoluble	Shu-Wen L., Chun-Jung L. and Jyh-Chin Y. (2017). Expert Opinion in Pharmacotherapy. Vol 18.
logP	5	Shu-Wen L., Chun-Jung L. and Jyh-Chin Y. (2017). Expert Opinion in Pharmacotherapy. Vol 18.
pKa	1.8	Stefano A., Rusca A., Loprete L., Droge M., Moro L. and Assandri A. (2011). Antimicrob Agents Chemother.

Predicted Properties

Property	Value	Source
Water Solubility	0.0147 mg/mL	ALOGPS
logP	4.15	ALOGPS
logP	4.17	Chemaxon
logS	-4.7	ALOGPS
pKa (Strongest Acidic)	7.09	Chemaxon
pKa (Strongest Basic)	-1.1	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	11	Chemaxon
Hydrogen Donor Count	6	Chemaxon
Polar Surface Area	201.31 Å2	Chemaxon
Rotatable Bond Count	3	Chemaxon
Refractivity	187.8 m3·mol-1	Chemaxon
Polarizability	72.6 Å3	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000t-0000009000-0372fcdb560ddf5022da
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0592-1000009000-efea59d1e6d3cb32977d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9000000000-e467f5002f9c5e056d87
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-052s-0000009000-8d646417a33dc9e71dd9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03fs-2000009000-5f49f8e572137fdaf7ec
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000t-0000009000-e2f4e57e940a0e6c1ac5

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	264.6304243	predicted	DarkChem Lite v0.1.0
[M-H]-	261.33533	predicted	DeepCCS 1.0 (2019)
[M+H]+	264.5424243	predicted	DarkChem Lite v0.1.0
[M+H]+	263.17422	predicted	DeepCCS 1.0 (2019)
[M+Na]+	264.1724243	predicted	DarkChem Lite v0.1.0
[M+Na]+	269.3163	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. DNA-directed RNA polymerase subunit beta

Kind

Protein

Organism

Escherichia coli (strain K12)

Pharmacological action

Yes

Actions

Binder

General Function

Ribonucleoside binding

Specific Function

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.

Gene Name

rpoB

Uniprot ID

P0A8V2

Uniprot Name

DNA-directed RNA polymerase subunit beta

Molecular Weight

150631.165 Da

References

1. Floss HG, Yu TW: Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. doi: 10.1021/cr030112j. [Article]

Details2. DNA-directed RNA polymerase subunit alpha

Kind

Protein

Organism

Escherichia coli (strain K12)

Pharmacological action

Yes

Actions

Binder

General Function

Zinc ion binding

Specific Function

DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. This subunit plays an important role in subunit assembly s...

Gene Name

rpoA

Uniprot ID

P0A7Z4

Uniprot Name

DNA-directed RNA polymerase subunit alpha

Molecular Weight

36511.35 Da

References

1. Floss HG, Yu TW: Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. doi: 10.1021/cr030112j. [Article]

Details3. DNA-directed RNA polymerase subunit beta'

Kind

Protein

Organism

Escherichia coli (strain K12)

Pharmacological action

Yes

Actions

Binder

General Function

Dna-directed rna polymerase activity

Specific Function

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.

Gene Name

rpoC

Uniprot ID

P0A8T7

Uniprot Name

DNA-directed RNA polymerase subunit beta'

Molecular Weight

155158.84 Da

References

1. Floss HG, Yu TW: Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. doi: 10.1021/cr030112j. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at October 20, 2016 20:45 / Updated at August 05, 2021 01:52